Ask the expert: How can hallucinations affect people with Parkinson’s?
Author: Saskia MairPublished: 14 January 2021
Prep: Cook: Serves:
Around 50% of people with Parkinson’s disease will experience hallucinations. But what are they – and what causes them? In the latest in our ‘Ask the expert’ series, Professor Per Odin shares what you need to know about the symptom
What are hallucinations?
Hallucinations are sensory experiences that appear real but are created by our brains. They can affect all five of our senses. You might hear voices that no one else hears, or see things that no one else sees. They are normally separate from illusions, which are distorted or misinterpreted real perceptions – for example, you could see a person where there is actually a tree.
What causes hallucinations in people with Parkinson’s disease?
Hallucinations are very common in Parkinson’s disease. More than half of patients experience them at some stage. They are normally thought to be an effect both of the condition itself and of Parkinson’s medication. The risk of hallucinations increases with cognitive impairment, longer disease duration, age and other diseases.
Visual (seeing) and auditory (hearing) hallucinations may occur as a side effect of antiparkinsonian drugs which are used to treat the condition. They are often dose-dependent – and in principle reversible.
What types of hallucinations can people with Parkinson’s experience?
Visual hallucinations are the most common in Parkinson’s disease. Auditory hallucinations occur mainly in depression. Tactile (touch) or olfactory (smell) sensations are unusual.
Often the symptom starts with lively dreams, then illusions, then hallucinations at night-time. After that hallucinations can also appear in the day. Initially the patient understands that the experience is a hallucination, but if things progress it becomes difficult to say what is real and not.
Further progression could mean that the hallucinations become scary, and patients can develop confusion or delusions (for example, believing that a partner is unfaithful). Auditive hallucinations are seldom linked to Parkinson’s.
Mild hallucinations do not need to impact life very much, and can even be experienced as entertaining in some cases. But when the hallucinations become more pronounced and it is difficult to differentiate them from reality, they can have a big effect.
Per Odin is a neurologist, professor and head of the neurology department at Lund University, Sweden.
Can hallucinations be treated?
The treatment for hallucinations consists primarily of removing any existing medical cause, especially reducing or stopping any triggering pharmacological cause – for example by reducing a dose or discontinuing treatment with a certain drug. If the increase in motor symptoms then becomes troublesome, a return to the earlier anti-Parkinson’s drug may be considered, but with the addition of an atypical neuroleptic drug.
Most neuroleptics (drugs against hallucinations and psychosis) can worsen Parkinson’s (sometimes dramatically) and are forbidden when treating people with the condition. Medications for dementia can also reduce the incidence of illusions and hallucinations when there is underlying cognitive impairment. Parkinson’s treatments are developing fast and it is likely that we will see even more effective ways of avoiding and treating hallucinations in the coming years.
The most important thing is to report hallucinations to your doctor or nurse, and to discuss if they should be treated in some way.
Do you have any advice for the family, friends and carers of people with Parkinson’s experiencing hallucinations?
Tell the patient that what they are experiencing is not real and do not pretend that you also experience the same thing. Be calm and friendly with the patient – experiencing hallucinations can be quite stressful.
Need to know
Per Odin is a neurologist, professor and head of the neurology department at Lund University, Sweden. He also works at an outpatient clinic in Bremen, Germany. He has focused on Parkinson’s disease, both clinically and in research, since 1987.
Helping people with Parkinson’s “take back control of their brain and body”
We talk to the founder of MyCognition
5 days ago
Researchers have finally identified brain cells linked to Parkinson’s disease
For decades, scientists have known that Parkinson’s is associated with the death of dopamine-producing cells in the brain. Now, researchers from the Broad Institute of MIT and Harvard, US, have discovered the specific subtype of brain cells that die in Parkinson’s disease. Using a technique called single-cell RNA signalling, which enables the individual analysis of cells within a tissue for activity and protein production, researchers identified 10 subtypes of dopamine-producing cells within the donated brains of people who died from causes unrelated to Parkinson’s. The team carried out the same investigation on people who had died with Parkinson’s or a condition with similar symptoms called Lewy body dementia. They discovered that only one subtype of the cells had reduced in number – which suggests many of these cells had died while the people were living. It is hoped that the findings could lead to better understanding of Parkinson’s causes and…
Tiny DBS implant shows potential to advance Parkinson’s disease treatment
In an innovative trial by North Bristol NHS Trust, UK, surgeons have succeeded in implanting a tiny deep brain stimulation (DBS) device into a person’s skull. Their aim? To address symptoms of Parkinson’s. Designed with a tiny battery system that is inserted into the skull, the DBS device delivers electric impulses to targeted areas of the brain through electric probes. In doing so, it works to address abnormal brain cell activity associated with Parkinson’s – and may help to ease symptoms. One of around 25 patients selected for the year-long trial has described the device’s impact as “amazing”. Commenting on the results of the trial so far, consultant neurologist Dr Alan Whone of North Bristol NHS Trust said: “We are hopeful that if these findings hold up, we will have a significant technical advance by which to improve Parkinson’s care across the world.”
Could a specialised smartwatch support people with Parkinson’s disease?
A specialised smartwatch, which could help those living with Parkinson’s to better manage their condition, will be rolled out to thousands of people in England. The Parkinson’s Kinetigraph, developed by the National Health Service (NHS) in Plymouth and the University of Plymouth, UK, contains sensors designed to monitor the wearer’s activity and buzz with medication reminders. Data collected from the watch – which detects excessive movement, immobility and sleep disturbances – is shared with healthcare providers, allowing for improvements to physiotherapy and prescriptions based on patient needs. Commenting on the smartwatch’s launch, NHS England chief executive Amanda Pritchard said: “Not only is it better for these people living with Parkinson’s, but it is also more efficient for the NHS, freeing up space and time in hospitals for our hard-working staff.” UK health secretary Sajid Javid, meanwhile, described the Kinetigraph as a “fantastic example of how technology is driving cutting-edge innovation…